Vontobel Holding Ltd. Aurinia Pharmaceuticals Inc. Transaction History

Vontobel Holding Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$4.93 - $9.31 $9,860 - $18,620	-2,000 Reduced 2.44%	80,000 $400,000
Q2 2023 Jun 03, 2024	BUY	$8.96 - $11.69 $93,184 - $121,576	10,400 Added 14.53%	82,000 $793,000
Q2 2023 Jul 24, 2023	BUY	$8.96 - $11.69 $93,184 - $121,576	10,400 Added 14.53%	82,000 $793,000
Q1 2023 Jun 03, 2024	SELL	$5.94 - $11.27 $49,896 - $94,668	-8,400 Reduced 10.5%	71,600 $784,000
Q1 2023 Apr 12, 2023	BUY	$5.94 - $11.27 $89,100 - $169,050	15,000 Added 26.5%	71,600 $784,000
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $106,860 - $211,640	26,000 Added 84.97%	56,600 $244,000
Q2 2022 Jul 27, 2022	BUY	$8.95 - $12.8 $41,170 - $58,880	4,600 Added 17.69%	30,600 $308,000
Q1 2022 May 13, 2022	BUY	$10.05 - $22.48 $107,535 - $240,536	10,700 Added 69.93%	26,000 $322,000
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $315,363 - $586,739	-17,737 Reduced 53.69%	15,300 $350,000
Q1 2021 May 11, 2021	SELL	$12.3 - $18.73 $77,403 - $117,867	-6,293 Reduced 16.0%	33,037 $429,000
Q4 2020 Feb 12, 2021	BUY	$12.94 - $16.05 $508,930 - $631,246	39,330 New	39,330 $544,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.